Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SP-8203 (Otaplimastat) with Thrombolysis in Acute Ischemic Stroke
NCT06660719Phase 3Recruiting
- Sponsor
- Shinpoong Pharma
- Start
- Feb 2025
- Primary completion
- Mar 2027
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in ischemic stroke comparing SP-8203 + SOC with Placebo + SOC (2 arms). Primary endpoint: Proportion of participants with modified Rankin Scale 0-1 at 90 days. Started Feb 2025; status: recruiting.
02
Drugs
otaplimastat
03
Conditions
ischemic stroke
Beyond the preview
Go deeper on NCT06660719.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06660719.